{
  "source": "PA-Notification-Erivedge.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1030-12\nProgram Prior Authorization/Notification\nMedication Erivedge® (vismodegib)\nP&T Approval Date 4/2012, 8/2012, 7/2013, 11/2014, 11/2015, 9/2016, 9/2017, 9/2018,\n9/2019, 9/2020, 10/2021, 10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nErivedge® (vismodegib) is a hedgehog pathway inhibitor indicated for the treatment of adults\nwith metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has\nrecurred following surgery or who are not candidates for surgery, and who are not candidates for\nradiation.1\nThe National Comprehensive Cancer Network (NCCN) also recommends Erivedge for the\ntreatment of medulloblastoma for recurrence as a single agent in patients who have received\nprior chemotherapy and have mutations in the sonic hedgehog pathway.2\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Erivedge will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Basal Cell Carcinoma\n1. Initial Authorization\na. Erivedge will be approved based on one of the following criteria:\n(1) Diagnosis of metastatic basal cell carcinoma\n-OR-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(2) Both of the following:\n(a) Diagnosis of locally advanced basal cell carcinoma\n-AND-\n(b) One of the following:\ni. Cancer has recurred following surgery\nii. Patient is not a candidate for surgery\niii. Patient is not a c",
    "wing:\n(a) Diagnosis of locally advanced basal cell carcinoma\n-AND-\n(b) One of the following:\ni. Cancer has recurred following surgery\nii. Patient is not a candidate for surgery\niii. Patient is not a candidate for radiation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Erivedge will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Erivedge\ntherapy\nAuthorization will be issued for 12 months.\nC. Medulloblastoma\n1. Initial Authorization\na. Erivedge will be approved based on all of the following criteria:\n(1) Diagnosis of medulloblastoma\n-AND-\n(2) Patient has mutations in the sonic hedgehog pathway\n-AND-\n(3) Patient has failed prior chemotherapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Erivedge will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Erivedge\ntherapy\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Erivedge [package insert]. South San Francisco, CA: Genentech, Inc.; March 2023.\n2. The NCCN Drugs and Biologics C",
    " program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Erivedge [package insert]. South San Francisco, CA: Genentech, Inc.; March 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/compendia-templates/compendia/nccn-compendia. Accessed\nSeptember 6, 2024.\nProgram Prior Authorization/Notification - Erivedge (vismodegib)\nChange Control\n11/2014 Annual review with no change to coverage criteria.\n11/2015 Annual review. Increased authorization from 10 months to 12 months.\nUpdated background & references.\n9/2016 Annual review. Verbiage change in coverage criteria from Member to\nPatient. Formatting changes to criteria with no change to clinical intent.\nUpdated background and references.\n9/2017 Annual review with no change to coverage criteria. Updated references.\n9/2018 Annual review with no change to coverage criteria. Updated references.\n9/2019 Annual review. Added coverage for medulloblastoma. Updated references.\nAdded general NCCN recommended review criteria.\n9/2020 Annual review with no changes to coverage criteria.\n10/2021 Annual review with no changes to coverage criteria.\n10/2022 Annual review with no changes to coverage criteria. Added state mandate.\nUpdated references.\n10/2023 Annual review with no changes to coverage criteria. Updated references.\n10/2024 Annual review with no changes to coverage criteria. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}